Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению


А. В. Смирнов, Е. М. Шилов, В. А. Добронравов, И. Г. Каюков, И. Н. Бобкова, М. Ю. Швецов, А. Н. Цыгин, А. М. Шутов

Рабочая группа членов Правления Научного общества нефрологов России

Литература



  1. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2007 гг. (Аналитический отчет по данным Российского регистра. Нефрология и диализ. 2009; 11(3): 144-233.

  2. Дедов И.И., Шестакова М.В., ред. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Издание второе. М., 2006.

  3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV пересмотр. Российские рекомендации. М., 2009.

  4. Добронравов В.А. Эпидемиология диабетической нефропатии: общие и региональные проблемы. Нефрология. 2002; 6(1):16-22.

  5. Добронравов В.А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза. Роль фактора роста фибробластов 23 и klotho. Нефрология. 2011; 15(4): 11-20.

  6. Добронравов В.А., Смирнов А.В., Драгунов С.В. и др. Эпидемиология хронической болезни почек в Вологодской области. Нефрология. 2004; 8(1): 36-41.

  7. Добронравов В.А., Смирнов А.В., Драгунов С.В. и др. Эпидемиология хронической почечной недостаточности в Северо-Западном регионе России: на пути к созданию регистра хронической почечной болезни. Тер. арх. 2004; 76(9): 57-61.

  8. Есаян А.М. Тканевая ренинангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология. 2008; 6(3): 8-16.

  9. Каюков И.Г., Смирнов А.В., Добронравов В.А. Рентгеноконтрастная нефропатия. Нефрология. 2007; 11(3): 93-101.

  10. Кучер А.Г., Каюков И.Г., Есаян А.М., Ермаков Ю.А. Влияние количества и качества белка в рационе надеятельность почек. Нефрология. 2004; 8(2): 14-34.

  11. Кучер А.Г., Каюков И.Г. Григорьева Н.Д., Васильев А.Н. Лечебное питание на различных стадиях хронической болезни почек. Нефрология и диализ. 2007; 9(2):118-136.

  12. Мухин Н.А., Балкаров И.М., Моисеев В.С. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер. арх. 2004; 76(9): 5-10.

  13. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. арх. 2004; (6):39-46.

  14. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии. М., 2008.

  15. Нефрология. Национальное руководство. Под ред. Н.А. Мухина. ГЭОТАР- Медиа. М., 2009, 720 с.

  16. Практические рекомендаци и KDIGO по диагностике, профилактике и лечению минеральных и костных нарушений при хронической болезни почек (ХБП-МКН). Краткое изложение рекомендаций. Нефрология. 2011; 15(1): 88-95.

  17. Смирнов А.В., Есаян А.М., Каюков И.Г. Хроническая болезнь почек на пути к единству представлений. Нефрология. 2002; 6(4): 11-17.

  18. Смирнов А.В. Дислипопротеидемии и проблемы нефропротекции. Нефрология. 2002; 6(2): 8-14.

  19. СмирновА.В., Каюков И.Г., Есаян А.М. и др. Превентивный подход в современной нефрологии. Нефрология. 2004;8(3): 7-14.

  20. Смирнов А.В., Добронравов В.А., Бодур-Ооржак А.Ш. и др. Эпидемиология и факторы риска хронических болезней почек региональный уровень общей проблемы. Тер. арх. 2005; (6): 20-27.

  21. Смирнов А.В., Добронравов В.А., Бодур-Ооржак А.Ш. и др. Распространенность и заболеваемость поздними стадиями хронической болезни почек в Республике Тыва. Нефрология. 2005; 9(4): 25-29.

  22. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум патогенетические основы превентивной нефрологии. Нефрология. 2005;9(3): 7-15.

  23. Смирнов А.В., Каюков И.Г., Есаян А.М. и др. Проблема оценки скорости клубочковой фильтрации в современной нефрологии, новый индикатор - цистатин С. Нефрология. 2005; 9(3): 16-27.

  24. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология. 2006; 10(1): 7-13.

  25. Смирнов А.В., Седов В.М., Лхаахуу Од-Эрдэнэ, Каюков И.Г. и др. Снижение скорости клубочковой фильтрации как независимый фактор риска сердечно-сосудистой болезни. Нефрология. 2006; 10(4): 7-17.

  26. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Рекомендации Научно­исследовательского института нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова: определение, классификация, диагностика и основные направления профилактики хронической болезни почек у взрослых. Левша, СПб., 2008;51.

  27. Смирнов А.В., Добронравов В.А., Каюков И.Г. Проблема модификации классификации и хронической болезни почек. Нефрология. 2010; 15(2): 7-15.

  28. Смирнов А.В., Кучер А.Г., Каюков И.Г., Есаян А.М. Руководство по лечебному питанию для больных хронической болезнью почек. Триада, СПб.-Тверь. 2009; 240.

  29. Шилов Е.М. Хроническая болезнь почек и программа народосбережения России. Саратов. 2011.

  30. Швецов М.Ю., Бобкова И.Н., Колина И.Б., Камышова Е.С. Современные принципы диагностики и лечения хронической болезни почек, методическое руководство для врачей. Шилов Е.М., ред. Саратов 2011.

  31. Шутов А.М., Саенко Ю.В. Плеотропные кардиопротективные эффекты эритропоэтина. Нефрология. 2006; 10(4): 18-22.

  32. Рrthoux F, Jones E, Gellert R et al. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995; Report of European Renal Association Registry and the National Registries. Nephrol Dial Transplant 1999; 14:2332-2342.

  33. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;. 17[Suppl]:11; 8-12.

  34. Brantsma A.H., Bakker S.J., Hillege H.L. et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005;28(10): 2525-2530.

  35. Burnier M., Phan O., Wang Q. High salt intake: a cause of blood pressure- independent left ventricular hypertrophy? Nephrol Dial Transplant 2007;22(9):2426-2429.

  36. Casas J.P., Chua W., Loukogeorgakis S. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366 (9502): 2026-2233.

  37. Chauveau P., Couzi L., Vendrely B. et al. Long-term outcome on renal replacement therapy in patients who previously received a keto acid- supplemented very-low-protein diet. Am J Clin Nutr 2009;90(4):969-974.

  38. Chen J., Munter P., Hamm L.Z. et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140: 167-174.

  39. Chobanian A.V., Bakris G.L., Black H.R. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7report. JAMA 2003;289(19):2560-2572.

  40. Cockcroft D.W., Gault M.H. Prediction of creatinine from serum creatinine. Nephron 1976;16(1): 31-41.

  41. Delanaye P., Cavalier E., Mariat C. et al. MDRD or CKDEPIstudy equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol 2010;11: 8. Published online 2010 June 1. doi: 10.1186/1471-2369-11-8].

  42. de Portu S., Citarella A., Cammarota S., Menditto E., Mantovani L.G. Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA. Clin Exp Hypertens 2011;33(3):174-178.

  43. Drueke T.B., Locatelli F., Clyne N. et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355(20): 2071-2084.

  44. European Best Practice Guidelines, Expert Group on Hemodialysis, European Renal Association. SectionI. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17[suppl 7]; 7-15.

  45. Foley R.N., Wang C., Snyder J.J., Collins A.J. Cystatin C levels in U.S. adults, 1988-1994 versus 1999-2002: NHANES. Clin J Am Soc Nephrol 2009; 4(5):965-972.

  46. Forman J.P., Brenner B.M. “Hypertension” and “microalbuminuria”: The bell tolls for thee. Kidney Int 2006; 69: 22-28.

  47. Fouque D., Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009;8;(3): CD001892.

  48. Fouque D., Pelletier S., Mafra D,. Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011; 80(4):348-357.

  49. Fried Z.F., Orchard T.J., Kasiske B.Z. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.

  50. Roissart M., Rossert J., Jacquot C., Paillard M., Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equationsfor estimating renal function. J Am Soc Nephrol 2005;16(3):763-773.

  51. Glynn L.G., Reddan D., Newell J. et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 2007; 22(9):2586-2594.

  52. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13):1296-305.

  53. Goodman W.G., London G., Amann K. et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43(3): 572-579.

  54. Hallan S., Asberg A., Lindberg M., Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44(1): 84-93.

  55. Hansen H.P., Tauber-Lassen E., Jensen B.R., Parving H.H. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62(1): 220-228.

  56. Haroun N.K., Jaar B.G., Hoffman S.C. et al. Risk factors for chronic Kidney disease: a prospective study of23.534 men and women in Washington Country, Maryland. J Am Soc Nephrol 2003; 14: 2934-2941.

  57. He J., Whelton P.K. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138(3 Pt 2): 211-219.

  58. Henry R.M., Kostense P.J., Bos G. et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407.

  59. Hsu C.-Y., Lin F., Vittinghoff E., Shlipac M.G. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the UnitedState. J Am Soc Nephrol 2003; 14: 2902-2907.

  60. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., Go A.S. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006 3;144(1):21-28.

  61. Ibrahim S., Rashid L., Darai M. Modification of diet in renal disease equation underestimates glomerular filtration rate in egyptian kidney donors. Exp Clin Transplant 2008;6(2):144-148.

  62. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-853.

  63. Jafar T.H., Stark P.C., Schmid C.H. et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244-252.

  64. Joint Speciality Committee on Renal Medicine of the RoyalCollege of Physicians and the Renal Association atRCoGP. Chronic Kidney Disease in adults: UK guidelines for management and referral. Royal College of Physicians, London: 2006

  65. Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290.

  66. Klahr S., Levey A.S., Beck G.J. et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877-884.

  67. Klausen K.P. Scharling H., Jensen G., Jensen J.S. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005; 46(1):33-37.

  68. Kopple J.D., FerozeU. The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 1(1):66-71.

  69. Krikken J.A., Lely A.T., Bakker S.J., Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71(3):260-265.

  70. Lentine K., Wrone E.M. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens 2004; 13(3):333-336.

  71. Levey A.S., Bosch J.P., Lewis J.B. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Ann Intern Med 1999;130(8): 461-470.

  72. Levey A.S., Greene T., Kusek J.W., Beck G.J. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.

  73. Levey A.S., Eckardt K.U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-20100.

  74. Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604-612.

  75. Levey A.S., de Jong P.E., Coresh J. et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; http:/www.kidney-international.org

  76. Locatelli F., Aljama P., Canaud B. et al. Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25(9): 2846-2850.

  77. Locatelli F., Covic A., Eckardt K.U. et al. ERA-DTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24:348-354.

  78. Locatelli F., Pozzoni P., Del Vecchio L. Epidemiology of chronic kidney disease in Italy: Possible therapeutical approaches. J Nephrol 2003; 16: 1-10.

  79. Lopez-Novoa J.M., Rodriguez-Pena A.B., Ortiz A. et al. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med 2011; 9:13. Published online 2011 Jan 20. doi: 10.1186/1479-5876-9-13.

  80. Ma Y.C., Zuo L., Chen J.H. et al. Modified glomerular filtration rate estima­ting equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17(10): 2937-2944.

  81. Maki D.D., Ma J.Z., Louis T.A., Kasiske B.L. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155(10):1073-1080.

  82. MacKinnon M., Shurraw S., Akbari A. et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48(1): 8-12.

  83. Mann J.F.E. Cardiovascular risk in patients with mild renal insufficiency: implication for the use of ACE inhibitors. La Presse Medicale 2005; 34(18): 1303-1308.

  84. Mann J.F., Schmieder R.E., McQueen M. et al. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.

  85. Matsuo S., Imai E., Horio M. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53(6):982-992.

  86. McClellan W.M., Flanders W.D. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003; 14: S65-S70.

  87. Meloni C., Morosetti M., Suraci C. et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 2002;12(2): 96-101.

  88. Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossini B, Cecilia A., Di Franco D., Straccialano E., Casciani C.U. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14(4):208-213.

  89. Mitch W.E. Dietary therapy in CKDpatients-the current status. Am J Nephrol 2005; 25[suppl.1]: 7-8.

  90. Muntner P., He J., Astor B.C. et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16:529-538.

  91. Majunath G., Tighionart H., Ibrahim H. et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.

  92. Macdougall I.C., TempleR.M., Kwan J.T. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 200722(3):784-793.

  93. Muntner P., Coresh J., Smith J.C. et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301.

  94. National Kidney Foundation K.D.: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39 [Suppl 1]: S1-S266.

  95. Nitsch D., Dietrich D.F., von Eckardstein A. et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21(4): 935-944.

  96. Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103-117.

  97. Pecoits-Filho R. Dietary protein intake and kidney disease in Western diet. Contrib Nephrol 2007;155:102-112.

  98. Peterson J.C., Adler S., Burkart J.M. et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123(10):754-762.

  99. Pijls L.T., de Vries H., van Eijk J.T., Donker A.J. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr 2002; 56(12):1200-1207.

  100. Pinto-Siersma S.J., Mulder J., Janssen W.M. et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133:585-591.

  101. Prakash S., Pande D.P., Sharma S. et al. Randomized, double-blind, placebo- controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. Ren Nut 2004; 14(2):89-96.

  102. Remuzzi G., Ruggenenti P., Perna A. et al. RENAAL Study Group Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15(12): 3117-3125.

  103. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther 2011; 29(1):77-87.

  104. Ritz E. Hypertension and kidney disease. Clin Nephrol 2010;74 [Suppl 1]: S39-43.

  105. Ritz E. Salt-friend orfoe? Nephrol Dial Transplant 2006;21(8):2052-2056.

  106. Ritz E, Dikow R, Morath C, Schwenger V. Salt-apotential, uremictoxin‘Blood Purif2006;24(1):63- 66.

  107. Rodger RSC, Williams B. Consensus conference on early chronic kidney disease. Foreword. Nephrol Dial Transplant 2007; 22 [suppl 9]: ix:1.

  108. Rodrigo E. et al. Measurement of renal function in preESRD patients. Kidney Int 2002; 61[Suppl 80]: S11-S17].

  109. Rule A.D., Larson T.S., Bergstralh E.J. et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141: 929-37.

  110. Rutkowski B. Changing pattern of end-stage renal failure in Central and Eastern Europe. Nephrol Dial Transplant 2002; 15: 156-160.

  111. Sacks F.M., Lichtenstein A., Van Horn L., Harris W., Kris Etherton P., Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol 2006;26(8):1689-1692.

  112. Saito A., Kaseda R., Hosojima M., Sato H. Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Int J Nephrol 2010 Dec 9;2011:957164.

  113. Schaeffner E.S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084-2091.

  114. Schmieder R.E. Schrader J., Zidek W. et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96(5):247- 257.

  115. Schiepati A., Remuzzi G. Chronic renal disease as a public health problem: Epidemiology, social and economic implications. Kidney Int 2005; 68[Suppl 98]: S7-S10.

  116. Segura J., Campo C., Ruilope L.M. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; [Suppl 92]:S45-S49.

  117. Silverberg D.S., Wexler D., Iaina A.The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 2004;17(6):749-761.

  118. Singh A.K., Szczech L., Tang K.L. et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-2098.

  119. Strippoli G.F., Navaneethan S.D., Johnson D.W. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336(7645):645-651.

  120. Teschan P.E., Beck G.J., Dwyer J.T. et al. Effect of a ketoacidaminoacid supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol 1998 50(5):273-283.

  121. Tanaka H., Shiohira Y., Uezu Y. et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006;69(2):369-374.

  122. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14):977-986.

  123. U.S. Renal Data System. USRDR 2004 Annual Data Report, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2004.

  124. Uribarri J., Tuttle K.R. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006 1(6):1293-1299.

  125. Vanholder R et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20(6):1048-1056.

  126. Warmoth L., Regalado M.M., Simoni J. et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330(3): 111-119.

  127. Weiner D.E., Tighiouart H., Levey A.S. et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007;18 (3):960-966.

  128. Wesson D.E., Nathan T., Rose T., Simoni J., Tran R.M. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007 71(3):210-221.

  129. Williams B., Poulter N.R., Brown M.J. et al. British Hypertension Society. Guidelinesfor management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHSIV. J Hum Hypertens 2004;18(3): 139-185.

  130. Xue J.L., Ma J.Z., Louis T.A., Collins A.J. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758.


Об авторах / Для корреспонденции


A. В. СМИРНОВ (САНКТ-ПЕТЕРБУРГСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. АКАД. И.П. ПАВЛОВА) ЧЛЕНЫ ГРУППЫ:
Е.М. ШИЛОВ (ПЕРВЫЙ МОСКОВСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. И.М. СЕЧЕНОВА);
B. А. ДОБРОНРАВОВ (САНКТ-ПЕТЕРБУРГСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. АКАД. И.П. ПАВЛОВА); И.Г. КАЮКОВ (САНКТ-ПЕТЕРБУРГСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. АКАД. И.П. ПАВЛОВА);
И.Н. БОБКОВА (ПЕРВЫЙ МОСКОВСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. И.М. СЕЧЕНОВА);
М.Ю. ШВЕЦОВ (ПЕРВЫЙ МОСКОВСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ИМ. И.М. СЕЧЕНОВА);
А.Н. ЦЫГИН (НАУЧНЫЙ ЦЕНТР ЗДОРОВЬЯ ДЕТЕЙ РОССИЙСКОЙ АКАДЕМИИ МЕДИЦИНСКИХ НАУК, МОСКВА);
А.М. ШУТОВ (УЛЬЯНОВСКИЙ ГОСУДАРСТВЕННЫЙ УНИВЕРСИТЕТ) .


Бионика Медиа